DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

18 Apr 2023

Y-mAbs Announces Presentation of Naxitamab data at AACR

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation featuring preclinical data on naxitamab, a recombinant, humanized anti-GD2 monoclonal antibody will be presented at the AACR Annual Meeting 2023, which takes place in Orlando, Florida from April 14-19, 2023. The poster, “Investigational novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells,” will be presented on April 18, 2023, from 1:30 to 5:00 pm EST.

The disialoganglioside GD2 has been shown to be upregulated in triple-negative breast cancer (“TNBC”) and its high expression is associated with a poor prognosis. Furthermore, breast cancer stem-like cells (“BCSCs”) are reported to be a major contributing factor for metastatic spread of TNBC and contribute to chemotherapy resistance, making them an important target for therapeutic intervention. Currently, there are no available therapeutic tools for targeting BCSCs. New preclinical data from M.D. Anderson Cancer Center demonstrate that TNBC with high GD2 expression inhibits immune cell infiltration and that naxitamab targets GD2+ BCSCs and may be able to inhibit the growth of BCSCs by enhancing macrophage-mediated phagocytosis, NK cell-mediated ADCC, and T cell-mediated cytotoxicity.

Y-mAbs provided naxitamab (DANYELZA) to this pre-clinical investigator sponsored study (“ISS”) at M.D. Anderson Cancer Center as part of its strategy to continue to support ISS studies.

Researchers at Memorial Sloan Kettering Cancer Center (“MSK”) developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. MSK has institutional financial interests related to the compound and Y-mAbs.

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

    Copyright 2023 DANISH BIO – DANSK BIOTEK. All rights reserved.